## Ariel Graff-Guerrero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2060417/publications.pdf

Version: 2024-02-01

183 papers 6,566 citations

66234 42 h-index 73 g-index

186 all docs

186
docs citations

186 times ranked 7997 citing authors

#	Article	IF	CITATIONS
1	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	4.0	685
2	Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Molecular Psychiatry, 2019, 24, 952-964.	4.1	225
3	Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis. Neuropsychopharmacology, 2011, 36, 1781-1791.	2.8	214
4	Kynurenine pathway in depression: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2018, 90, 16-25.	2.9	199
5	Glutamate Levels in the Associative Striatum Before and After 4 Weeks of Antipsychotic Treatment in First-Episode Psychosis. JAMA Psychiatry, 2013, 70, 1057.	6.0	175
6	The potential role of dopamine D3 receptor neurotransmission in cognition. European Neuropsychopharmacology, 2013, 23, 799-813.	0.3	153
7	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Research, 2012, 197, 1-6.	1.7	148
8	Temporal Difference Modeling of the Blood-Oxygen Level Dependent Response During Aversive Conditioning in Humans: Effects of Dopaminergic Modulation. Biological Psychiatry, 2007, 62, 765-772.	0.7	138
9	Repetitive transcranial magnetic stimulation of dorsolateral prefrontal cortex increases tolerance to human experimental pain. Cognitive Brain Research, 2005, 25, 153-160.	3.3	129
10	Motivational Deficits and Cognitive Test Performance in Schizophrenia. JAMA Psychiatry, 2014, 71, 1058.	6.0	122
11	Dopamine D2 Receptor Occupancy and Clinical Effects. Journal of Clinical Psychopharmacology, 2011, 31, 497-502.	0.7	117
12	Glutamate-mediated excitotoxicity in schizophrenia: A review. European Neuropsychopharmacology, 2014, 24, 1591-1605.	0.3	115
13	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Frontiers in Psychiatry, 2018, 9, 622.	1.3	115
14	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study. Neuropsychopharmacology, 2009, 34, 1078-1086.	2.8	109
15	Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophrenia Research, 2011, 133, 54-62.	1.1	99
16	The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. Archives of General Psychiatry, 2009, 66, 606.	13.8	97
17	Brain region binding of the D2/3 agonist $[11C]$ -(+)-PHNO and the D2/3 antagonist $[11C]$ raclopride in healthy humans. Human Brain Mapping, 2008, 29, 400-410.	1.9	95
18	Effect of electroconvulsive therapy on hippocampal and amygdala volumes: systematic review and meta-analysis. British Journal of Psychiatry, 2018, 212, 19-26.	1.7	94

#	Article	lF	CITATIONS
19	Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. Biological Psychiatry, 2019, 85, 596-605.	0.7	94
20	Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. Schizophrenia Bulletin, 2016, 42, 415-424.	2.3	80
21	Structural and functional alterations of the suicidal brain: An updated review of neuroimaging studies. Psychiatry Research - Neuroimaging, 2018, 278, 77-91.	0.9	80
22	Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. Journal of Psychopharmacology, 2018, 32, 509-523.	2.0	79
23	Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. International Journal of Neuropsychopharmacology, 2013, 16, 471-475.	1.0	78
24	Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 2011, 31, 318-325.	0.7	77
25	Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. JAMA Psychiatry, 2015, 72, 927.	6.0	77
26	Neuroimaging findings in treatment-resistant schizophrenia: A systematic review. Schizophrenia Research, 2015, 164, 164-175.	1.1	75
27	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level. JAMA Psychiatry, 2021, 78, 667.	6.0	72
28	Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation. Schizophrenia Bulletin, 2015, 41, 44-56.	2.3	69
29	Psychosis in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2014, 42, 485-499.	1.2	66
30	Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy. International Journal of Neuropsychopharmacology, 2016, 19, pyv105.	1.0	66
31	Prefrontal and Striatal Gamma-Aminobutyric AcidÂLevels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients. Biological Psychiatry, 2018, 83, 475-483.	0.7	66
32	Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. International Journal of Neuropsychopharmacology, 2010, 13, 273.	1.0	63
33	The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry Research, 2018, 268, 114-122.	1.7	62
34	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. Molecular Psychiatry, 2022, 27, 744-757.	4.1	60
35	Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans. International Journal of Neuropsychopharmacology, 2015, 18, pyv014-pyv014.	1.0	59
36	The effects of aging on insight into illness in schizophrenia: a review. International Journal of Geriatric Psychiatry, 2014, 29, 1145-1161.	1.3	58

3

#	Article	IF	Citations
37	Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: Resting state functional connectivity. Schizophrenia Research, 2014, 160, 43-50.	1.1	58
38	Ventral Striatum Binding of a Dopamine D2/3 Receptor Agonist But Not Antagonist Predicts Normal Body Mass Index. Biological Psychiatry, 2015, 77, 196-202.	0.7	53
39	Can we accurately classify schizophrenia patients from healthy controls using magnetic resonance imaging and machine learning? A multi-method and multi-dataset study. Schizophrenia Research, 2019, 214, 3-10.	1.1	53
40	Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology, 2020, 45, 632-640.	2.8	50
41	Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 45, 907-919.	1.2	49
42	Neurometabolite levels in antipsychotic-naÃ-ve/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 340-352.	2.5	49
43	Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity. Neuropsychopharmacology, 2016, 41, 2606-2613.	2.8	48
44	Acute and long-term effects of electroconvulsive therapy on human dentate gyrus. Neuropsychopharmacology, 2019, 44, 1805-1811.	2.8	48
45	Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. Neuropharmacology, 2020, 168, 107634.	2.0	48
46	Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. Journal of Psychopharmacology, 2019, 33, 1199-1214.	2.0	47
47	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Molecular Psychiatry, 2022, 27, 2950-2967.	4.1	44
48	Correlation between cerebral blood flow and items of the Hamilton Rating Scale for Depression in antidepressant-naive patients. Journal of Affective Disorders, 2004, 80, 55-63.	2.0	42
49	The VAGUS insight into psychosis scale – Self-report and clinician-rated versions. Psychiatry Research, 2014, 220, 1084-1089.	1.7	41
50	A meta-analysis of transcranial direct current stimulation for schizophrenia: "ls more better?― Journal of Psychiatric Research, 2019, 110, 117-126.	1.5	40
51	Frontotemporoparietal asymmetry and lack of illness awareness in schizophrenia. Human Brain Mapping, 2013, 34, 1035-1043.	1.9	38
52	Cortical Amyloid $\hat{l}^2$ Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 149-159.	1.2	38
53	Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. NPJ Schizophrenia, 2021, 7, 22.	2.0	35
54	Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 11-22.	1.8	34

#	Article	IF	CITATIONS
55	Cerebral blood flow changes associated with experimental pain stimulation in patients with major depression. Journal of Affective Disorders, 2008, 107, 161-168.	2.0	33
56	Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 743-754.	1.2	33
57	Brain degeneration in Parkinson's disease patients with cognitive decline: a coordinate-based meta-analysis. Brain Imaging and Behavior, 2019, 13, 1021-1034.	1.1	33
58	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophrenia Research, 2015, 161, 351-356.	1.1	32
59	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. Schizophrenia Research, 2019, 208, 420-429.	1.1	32
60	Functional magnetic resonance imaging response to experimental pain in drug-free patients with schizophrenia. Psychiatry Research - Neuroimaging, 2010, 183, 99-104.	0.9	31
61	Estimating Endogenous Dopamine Levels at D2 and D3 Receptors in Humans using the Agonist Radiotracer [11C]-(+)-PHNO. Neuropsychopharmacology, 2014, 39, 2769-2776.	2.8	31
62	Altered functional connectivity in brain networks underlying self-referential processing in delusions of reference in schizophrenia. Psychiatry Research - Neuroimaging, 2017, 263, 32-43.	0.9	31
63	Brain insulin action in schizophrenia: Something borrowed and something new. Neuropharmacology, 2020, 163, 107633.	2.0	31
64	Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. Journal of Psychiatric Research, 2020, 124, 151-158.	1.5	31
65	Abnormal white matter integrity in antipsychotic-na $\tilde{A}$ -ve first-episode psychosis patients assessed by a DTI principal component analysis. Schizophrenia Research, 2015, 162, 14-21.	1.1	30
66	Examining endogenous dopamine in treated schizophrenia using [11C]-(+)-PHNO positron emission tomography: A pilot study. Clinica Chimica Acta, 2015, 449, 60-62.	0.5	29
67	Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression. Journal of Alzheimer's Disease, 2020, 76, 733-751.	1.2	27
68	Lack of Age-Dependent Decrease in Dopamine D3 Receptor Availability: A [11C]-(+)-PHNO and [11C]-Raclopride Positron Emission Tomography Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1812-1818.	2.4	26
69	Non-Pharmacological Management for Patients with Frontotemporal Dementia: A Systematic Review. Journal of Alzheimer's Disease, 2015, 45, 283-293.	1.2	26
70	The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2016, 17, 1766.	1.8	26
71	Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 178-182.	2.5	25
72	Is desire for social relationships mediated by the serotonergic system in the prefrontal cortex? An [ <sup>18</sup> F]setoperone PET study. Social Neuroscience, 2010, 5, 375-383.	0.7	24

#	Article	lF	CITATIONS
73	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. American Journal of Geriatric Psychiatry, 2014, 22, 1007-1016.	0.6	24
74	Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans. Neuropsychopharmacology, 2016, 41, 529-537.	2.8	24
75	Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2016, 54, 615-633.	1.2	23
76	Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans. European Neuropsychopharmacology, 2016, 26, 644-652.	0.3	23
77	Psychiatric benefits of lithium in water supplies may be due to protection from the neurotoxicity of lead exposure. Medical Hypotheses, 2018, 115, 94-102.	0.8	23
78	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. Schizophrenia Research, 2015, 161, 429-433.	1.1	22
79	Neuroimaging correlates of narcolepsy with cataplexy: A systematic review. Neuroscience Research, 2019, 142, 16-29.	1.0	22
80	White matter microstructural organizations in patients with severe treatment-resistant schizophrenia: A diffusion tensor imaging study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 100, 109871.	2.5	21
81	Vaccine Hesitancy Is a Barrier to Achieving Equitable Herd Immunity Among Racial Minorities. Frontiers in Medicine, 2021, 8, 668299.	1.2	20
82	Benzodiazepine Use Attenuates Cortical $\hat{l}^2$ -Amyloid and is Not Associated with Progressive Cognitive Decline in Nondemented Elderly Adults: A Pilot Study Using F18-Florbetapir Positron Emission Tomography. American Journal of Geriatric Psychiatry, 2016, 24, 1028-1039.	0.6	19
83	Brain insulin action: Implications for the treatment of schizophrenia. Neuropharmacology, 2020, 168, 107655.	2.0	19
84	Adiposity in schizophrenia: A systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2021, 144, 524-536.	2.2	19
85	Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2017, 25, 1-10.	0.6	18
86	Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophreniaâ€"A [11C]-raclopride PET study. Schizophrenia Research, 2015, 164, 263-267.	1.1	17
87	The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 65, 49-53.	2.5	17
88	Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532210965.	1.2	17
89	Neural response to experimental heat pain in stable patients with schizophrenia. Journal of Psychiatric Research, 2012, 46, 128-134.	1.5	16
90	Dopamine D2/3Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. Schizophrenia Bulletin, 2015, 42, sbv106.	2.3	16

#	Article	IF	CITATIONS
91	Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. Experimental Eye Research, 2018, 175, 32-41.	1.2	16
92	What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy. Neuropharmacology, 2020, 163, 107591.	2.0	16
93	Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 99, 109839.	2.5	16
94	Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics. Schizophrenia Research, 2009, 109, 130-133.	1.1	15
95	Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology, 2013, 228, 43-51.	1.5	15
96	Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 83-91.	2.5	15
97	l'-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. American Journal of Geriatric Psychiatry, 2016, 24, 923-939.	0.6	15
98	Resting-state functional connectivity in treatment response and resistance in schizophrenia: A systematic review. Schizophrenia Research, 2019, 211, 10-20.	1.1	15
99	Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review. Nutrients, 2020, 12, 3883.	1.7	15
100	Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. Psychiatry Research - Neuroimaging, 2018, 273, 16-24.	0.9	14
101	Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. Schizophrenia Bulletin Open, 2021, 2, sgab006.	0.9	14
102	Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. Translational Psychiatry, 2021, 11, 219.	2.4	14
103	Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2022, 132, 1205-1213.	2.9	13
104	Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110473.	2.5	13
105	Estimating the effect of endogenous dopamine on baseline [ <sup>11</sup> C]â€(+)â€PHNO binding in the human brain. Synapse, 2016, 70, 453-460.	0.6	12
106	Exploring the relationship between social attachment and dopamine D <sub>2/3</sub> receptor availability in the brains of healthy humans using [ <sup>11</sup> C]-(+)-PHNO. Social Neuroscience, 2017, 12, 163-173.	0.7	12
107	The relationship between subcortical brain volume and striatal dopamine D <sub>2/3</sub> receptor availability in healthy humans assessed with [ <sup>11</sup> C]â€raclopride and [ <sup>11</sup> C]â€(+)â€PHNO PET. Human Brain Mapping, 2017, 38, 5519-5534.	1.9	12
108	Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. European Psychiatry, 2019, 61, 63-71.	0.1	12

#	Article	IF	CITATIONS
109	Structural Brain Differences Between Cognitively Impaired Patients With and Without Apathy. American Journal of Geriatric Psychiatry, 2021, 29, 319-332.	0.6	12
110	Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels. Journal of Psychiatry and Neuroscience, 2022, 47, E1-E10.	1.4	12
111	Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Medical Hypotheses, 2015, 85, 391-396.	0.8	11
112	Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology, 2016, 233, 3803-3813.	1.5	11
113	Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. International Journal of Geriatric Psychiatry, 2018, 33, 523-530.	1.3	11
114	Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity. NPJ Schizophrenia, 2019, 5, 8.	2.0	11
115	Threshold of Dopamine D <sub>2/3</sub> Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, e1557-e1563.	1.1	11
116	Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults. BMC Medical Imaging, 2009, 9, 12.	1.4	10
117	Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. Psychoneuroendocrinology, 2017, 81, 80-87.	1.3	10
118	Trait impulsiveness is related to smaller postâ€commissural putamen volumes in males but not females. European Journal of Neuroscience, 2017, 46, 2253-2264.	1.2	10
119	Reward motivation in humans and its relationship to dopamine D2/3 receptor availability: A pilot study with dual [11C]-raclopride and [11C]-(+)-PHNO imaging. Journal of Psychopharmacology, 2018, 32, 357-366.	2.0	10
120	Amyloid deposition in semantic dementia: a positron emission tomography study. International Journal of Geriatric Psychiatry, 2016, 31, 1064-1074.	1.3	9
121	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2017, 58, 747-762.	1.2	9
122	The neural correlates of apathy in schizophrenia: An exploratory investigation. Neuropsychologia, 2018, 118, 34-39.	0.7	9
123	Lead (Pb) in Alzheimer's Dementia: A Systematic Review of Human Case- Control Studies. Current Alzheimer Research, 2019, 16, 353-361.	0.7	9
124	Measuring amphetamineâ€induced dopamine release in humans: A comparative metaâ€analysis of [ <sup>11</sup> C]â€raclopride and [ <sup>11</sup> C]â€(+)â€PHNO studies. Synapse, 2021, 75, e22195.	0.6	9
125	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. Neurolmage: Clinical, 2021, 32, 102852.	1.4	9
126	Trait impulsivity is not related to post-commissural putamen volumes: A replication study in healthy men. PLoS ONE, 2018, 13, e0209584.	1.1	7

#	Article	IF	CITATIONS
127	DAS: The Diabetes Awareness and Insight Scale. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 189-194.	1.8	7
128	Vestibular stimulation improves insight into illness in schizophrenia spectrum disorders. Psychiatry Research, 2017, 251, 333-341.	1.7	6
129	Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. European Neuropsychopharmacology, 2018, 28, 285-296.	0.3	6
130	Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment. Journal of Neuroimaging, 2019, 29, 721-729.	1.0	6
131	Graph theory analysis of the dopamine D2 receptor network in Parkinson's disease patients with cognitive decline. Journal of Neuroscience Research, 2021, 99, 947-965.	1.3	6
132	Does Family History of Alcohol Use Disorder Relate to Differences in Regional Brain Volumes? A Descriptive Review with New Data. Alcoholism: Clinical and Experimental Research, 2018, 42, 2369-2384.	1.4	5
133	Subiculum volumes associated with memory function in the oldestâ€old individuals aged 95 years and older. Geriatrics and Gerontology International, 2019, 19, 347-351.	0.7	5
134	The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 207-213.	2.5	5
135	Impaired Awareness of Problem and Pathological Gambling: A Review. Journal of Gambling Studies, 2020, 36, 39-50.	1.1	5
136	Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia. Schizophrenia Research, 2020, 223, 279-288.	1.1	5
137	Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia. Neuropsychopharmacology Reports, 2020, 40, 138-149.	1.1	5
138	The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report. Journal of Alzheimer's Disease, 2017, 60, 341-347.	1.2	4
139	Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia. Journal of Psychiatric Research, 2021, 136, 468-473.	1.5	4
140	A Measure to Assess Illness Awareness in Problem Gambling: Gambling Awareness and Insight Scale (GAS). Journal of Gambling Studies, 2021, , 1.	1.1	4
141	A measure of illness awareness in alcohol use disorderâ€"Alcohol Use Awareness and Insight Scale (AAS). Drug and Alcohol Dependence, 2021, 226, 108813.	1.6	4
142	Investigation of accelerated epigenetic aging in individuals suffering from schizophrenia in the context of lifetime suicide attempt. Schizophrenia Research, 2022, 243, 222-224.	1.1	3
143	Dorsolateral prefrontal cortex metabolites and their relationship with plasticity in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e045879.	0.4	3
144	A measure of subjective substance use disorder awareness – Substance Use Awareness and Insight Scale (SAS). Drug and Alcohol Dependence, 2022, 231, 109129.	1.6	3

#	Article	IF	CITATIONS
145	Anti-vaccination attitudes are associated with less analytical and more intuitive reasoning. Psychology, Health and Medicine, 2021, , 1-13.	1.3	3
146	Is antipsychotic sensitivity in Alzheimer's disease secondary to abnormal blood–brain barrier integrity?. Brain, 2017, 140, 865-867.	3.7	2
147	Cross-cultural psychometric assessment of the VAGUS insight into psychosis scale – Spanish version. Psychiatry Research, 2018, 259, 450-454.	1.7	2
148	F230. Glutamatergic Neurometabolite Levels in Patients With Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton MRS Study. Biological Psychiatry, 2018, 83, S328.	0.7	2
149	Reprint of OASIS – Obesity Awareness and Insight Scale. Primary Care Diabetes, 2018, 12, 371-378.	0.9	2
150	S46. A Systematic Review of Case-Control Human Studies of Lead (Pb) in Alzheimer's Dementia. Biological Psychiatry, 2019, 85, S314.	0.7	2
151	Thetaâ€gamma coupling and ApoE genotype in patients at risk for Alzheimer's dementia. Alzheimer's and Dementia, 2020, 16, e047573.	0.4	2
152	MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. British Journal of Clinical Pharmacology, 2022, 88, 3341-3350.	1.1	2
153	The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans. European Neuropsychopharmacology, 2022, 57, 39-49.	0.3	2
154	Impaired illness awareness and leftward visuospatial inattention in schizophrenia are attributable to a common neural deficit – Posterior parietal hemispheric imbalance. Medical Hypotheses, 2017, 100, 19-22.	0.8	1
155	Further in vivo characterization of [ <sup>11</sup> C]â€(+)â€PHNO uptake into a retinaâ€like region of interest in humans. Synapse, 2020, 74, e22135.	0.6	1
156	Lower striatal dopamine D2/3receptor availability in obsessive-compulsive disorder: A meta-analysis of [11C]-raclopride and [123I]-IBZM studies. Journal of Obsessive-Compulsive and Related Disorders, 2021, 28, 100618.	0.7	1
157	Propiedades psicométricas de la Escala de Gaudibilidad (Moduladores de Disfrute) para Niños y Adolescentes (EGNA) Anales De Psicologia, 2021, 37, 69-76.	0.3	1
158	Measuring Amphetamine-Induced Dopamine Release in Humans: A Comparative Meta-Analysis of [11C]-Raclopride and [11C]-(+)-PHNO Studies. Biological Psychiatry, 2021, 89, S94-S95.	0.7	1
159	Neuromelanin Accumulation in Patients With Schizophrenia: A Systematic Review and Meta-Analysis. Biological Psychiatry, 2021, 89, S253.	0.7	1
160	Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia. Schizophrenia Research, 2022, 241, 113-115.	1.1	1
161	Childhood trauma exposure and personality traits in schizophrenia patients. Schizophrenia Research, 2022, 241, 221-227.	1.1	1
162	Reply to â€~Letter in reference to de la Fuente-Sandoval, C. et al. Neuropsychopharmacology 36, 1781–1791, 2011'. Neuropsychopharmacology, 2012, 37, 1069-1069.	2.8	O

#	Article	IF	CITATIONS
163	F4â€02â€01: ALGORITHMIC APPROACH TO THE MANAGEMENT OF AGITATION AND AGGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1383.	S <sub>0.4</sub>	O
164	F6. Is it Possible to Elicit Progressive Functioning Decline Without Having Beta-Amyloid Pathology? Clinical Trajectories of Mild Cognitive Impairment With Suspected Non-Alzheimer's Pathology. Biological Psychiatry, 2018, 83, S239.	0.7	0
165	T199. Assessing Neurometabolite Alterations in theÂAnterior Cingulate Cortex of Patients With Schizophrenia: A Multi-Site Proton Magnetic Resonance Spectroscopy Initiative. Biological Psychiatry, 2019, 85, S207.	0.7	O
166	S43. Structural Brain Differences Between Cognitively Impaired Patients With and Without Apathy. Biological Psychiatry, 2019, 85, S313.	0.7	O
167	F182. Improving Insight into Psychosis With Transcranial Direct Current Stimulation in Schizophrenia. Biological Psychiatry, 2019, 85, S284.	0.7	O
168	S167. Increased N-Acetylaspartate and Myo-Inositol Levels in Clozapine-Responders and Clozapine-Resistant Patients With Schizophrenia. Biological Psychiatry, 2019, 85, S361-S362.	0.7	0
169	S185. Treatment Response Trajectories in Treatment-Resistant Schizophrenia: A Chart Review Study. Biological Psychiatry, 2019, 85, S368-S369.	0.7	O
170	M23. ALTERATION OF REGIONAL CEREBRAL BLOOD FLOW MEASURED BY ARTERIAL SPIN LABELING IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S142-S142.	2.3	0
171	M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY. Schizophrenia Bulletin, 2020, 46, S166-S166.	2.3	O
172	M157. A MULTICENTRE STUDY OF 1H-MRS BRAIN GLUTAMATE LEVELS IN SCHIZOPHRENIA; INVESTIGATING THE EFFECT OF ANTIPSYCHOTIC MEDICATION, SYMPTOM SEVERITY AND AGE. Schizophrenia Bulletin, 2020, 46, S195-S196.	2.3	0
173	T212. LEVELS OF GLUTAMATERGIC NEUROMETABOLITES IN PATIENTS WITH SEVERE TREATMENT-RESISTANT SCHIZOPHRENIA: A PROTON MAGNETIC RESONANCE SPECTROSCOPY STUDY. Schizophrenia Bulletin, 2020, 46, S313-S313.	2.3	O
174	Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study. Biological Psychiatry, 2020, 87, S414.	0.7	0
175	Cortical Thickness in Patients With Schizophrenia With Impaired Insight Into Illness. Biological Psychiatry, 2021, 89, S181-S182.	0.7	O
176	Linking Clozapine/Norclozapine Ratio with Glial Marker in Patients With Treatment Resistant Schizophrenia. Biological Psychiatry, 2021, 89, S252.	0.7	0
177	GWAS Analysis of Insight in Schizophrenia. Biological Psychiatry, 2021, 89, S136-S137.	0.7	O
178	Differences in Cortical Thickness Associated With Apathy in Cognitively Impaired Persons. Biological Psychiatry, 2021, 89, S273-S274.	0.7	0
179	Increased Regional Cerebral Blood Flow in the Parietal Regions in Patients With Schizophrenia With Impaired Insight. Biological Psychiatry, 2021, 89, S263-S264.	0.7	O
180	Theta Phase-Gamma Amplitude Coupling During Working Memory and its Relationships With Demographic, Clinical, Genetic, Neurochemical, and Neurostructural Measures in Older Adults at Risk for Dementia. Biological Psychiatry, 2021, 89, S350-S351.	0.7	0

#	Article	IF	CITATIONS
181	Improving Insight in Non-Treatment-Resistant Patients With Schizophrenia With Transcranial Direct Current Stimulation. Biological Psychiatry, 2020, 87, S186.	0.7	O
182	Tracking the Temporal Footprint Effect of Thermonociception and Denervation on the Brain's Pain Matrix: fMRI and BOLD Study in Rats. Journal of Pain Research, 2022, Volume 15, 857-865.	0.8	0
183	Differential Methylation Analysis of Suicidal Ideation Severity in Schizophrenia with the Illumina MethylationEPIC Array. Healthcare (Switzerland), 2022, 10, 809.	1.0	0